Researchers from The University of Alabama at Birmingham have shown a therapeutic effect of Rho kinase inhibitors in idiopathic pulmonary fibrosis. Although the results suggest a repurposing opportunity for the molecules, a lung-specific formulation of the inhibitors will be required to avoid systemic side effects.